ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0047

Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis
Abstract Number: 1270

Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients
Abstract Number: 0600

Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline
Abstract Number: 2336

Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
Abstract Number: 1941

Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Abstract Number: 1084

Identifying and Addressing Disparities in Health Literacy in Patients with Rheumatic Diseases Through Point of Care Distribution of Patient Education Materials
Abstract Number: 1909

Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease
Abstract Number: 0131

Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model
Abstract Number: 1520

Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method
Abstract Number: 1444

Identifying Determinants of Favourable and Poor Physical Function in Systemic Lupus Erythematosus: Results from an International Collaborative Study
Abstract Number: 2235

Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis
Abstract Number: 1642

Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort
Abstract Number: 0978

Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model
Abstract Number: 2262

Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study
Abstract Number: 1008

Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].